Drug Profile
KN 044
Alternative Names: KN-044Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in China
- 15 Oct 2019 Changchun Intellicrown Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) (IV, infusion) (NCT04126590)
- 15 Jul 2016 Early research in Cancer in China (unspecified route)